Adalvo today announced the signing of a distribution partnership that will bring one of its most technically differentiated oncology assets to patients across the United States and Canada. The agreement with Cipla USA Inc., (the wholly owned subsidiary of Cipla Limited) represents another important step in Adalvo’s continued expansion of its commercial footprint in North America.
The agreement marks a further expansion of Adalvo's commercial footprint in North America. The product will be filed as a 505(b)(2) application in the US and as a Value-Added Medicine in Canada.
The two regulatory pathways highlight the formulation’s complexity, which Adalvo has successfully managed.
Commenting on the partnership, Anil Okay, CEO of Adalvo, said: "This agreement reflects our strategic ambition to expand our reach across North America, while delivering differentiated, cost-effective treatments to overlooked patient populations."
The partnership underlines Adalvo's ability to take technically complex products through demanding regulatory processes and into commercial distribution through best-in-class partners — a model that continues to drive its growth across key global markets.